Gould RJ - Search Results

1

Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp.

Egbertson MS, Chang CT, Duggan ME, Gould RJ, Halczenko W, Hartman GD, Laswell WL, Lynch JJ Jr, Lynch RJ, Manno PD, et al. Egbertson MS, et al. Among authors: gould rj. J Med Chem. 1994 Aug 5;37(16):2537-51. doi: 10.1021/jm00042a007. J Med Chem. 1994. PMID: 8057299

2

Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist.

Duggan ME, Naylor-Olsen AM, Perkins JJ, Anderson PS, Chang CT, Cook JJ, Gould RJ, Ihle NC, Hartman GD, Lynch JJ, et al. Duggan ME, et al. Among authors: gould rj. J Med Chem. 1995 Aug 18;38(17):3332-41. doi: 10.1021/jm00017a017. J Med Chem. 1995. PMID: 7650686

3

Non-peptide glycoprotein IIb/IIIa antagonists. 11. Design and in vivo evaluation of 3,4-dihydro-1 (1H)-isoquinolinone-based antagonists and ethyl ester prodrugs.

Hutchinson JH, Cook JJ, Brashear KM, Breslin MJ, Glass JD, Gould RJ, Halczenko W, Holahan MA, Lynch RJ, Sitko GR, Stranieri MT, Hartman GD. Hutchinson JH, et al. Among authors: gould rj. J Med Chem. 1996 Nov 8;39(23):4583-91. doi: 10.1021/jm9604787. J Med Chem. 1996. PMID: 8917647

4

Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists.

Askew BC, Bednar RA, Bednar B, Claremon DA, Cook JJ, McIntyre CJ, Hunt CA, Gould RJ, Lynch RJ, Lynch JJ Jr, Gaul SL, Stranieri MT, Sitko GR, Holahan MA, Glass JD, Hamill T, Gorham LM, Prueksaritanont T, Baldwin JJ, Hartman GD. Askew BC, et al. Among authors: gould rj. J Med Chem. 1997 Jun 6;40(12):1779-88. doi: 10.1021/jm9608117. J Med Chem. 1997. PMID: 9191954

5

Nonpeptide glycoprotein IIb/IIIa inhibitors: substituted quinazolinediones and quinazolinones as potent fibrinogen receptor antagonists.

Liverton NJ, Armstrong DJ, Claremon DA, Remy DC, Baldwin JJ, Lynch RJ, Zhang G, Gould RJ. Liverton NJ, et al. Among authors: gould rj. Bioorg Med Chem Lett. 1998 Mar 3;8(5):483-6. doi: 10.1016/s0960-894x(98)00047-x. Bioorg Med Chem Lett. 1998. PMID: 9871603

6

Nonpeptide glycoprotein IIB/IIIA inhibitors. 19. A new design paradigm employing linearly minimized, centrally constrained, exosite inhibitors.

Hartman GD, Duggan ME, Hoffman WF, Meissner RJ, Perkins JJ, Zartman AE, Naylor-Olsen AM, Cook JJ, Glass JD, Lynch RJ, Zhang G, Gould RJ. Hartman GD, et al. Among authors: gould rj. Bioorg Med Chem Lett. 1999 Mar 22;9(6):863-8. doi: 10.1016/s0960-894x(99)00104-3. Bioorg Med Chem Lett. 1999. PMID: 10206551

7

Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation.

Egbertson MS, Cook JJ, Bednar B, Prugh JD, Bednar RA, Gaul SL, Gould RJ, Hartman GD, Homnick CF, Holahan MA, Libby LA, Lynch JJ Jr, Lynch RJ, Sitko GR, Stranieri MT, Vassallo LM. Egbertson MS, et al. Among authors: gould rj. J Med Chem. 1999 Jul 1;42(13):2409-21. doi: 10.1021/jm980722p. J Med Chem. 1999. PMID: 10395482

8

Nonpeptide GPIIB/IIIA receptor antagonists. Part 21: C-6 flexibility and amide bond orientation are important factors in determining the affinity of compounds for activated or resting platelet receptors.

Egbertson MS, Bednar B, Askew BC, Bednar RA, Brashear K, Breslin MJ, Duggan ME, Fisher TE, Halczenko W, Hutchinson JH, Ihle N, Prugh JD, Wai JS, Gould RJ, Hartman GD. Egbertson MS, et al. Among authors: gould rj. Bioorg Med Chem Lett. 2000 Sep 4;10(17):1943-8. doi: 10.1016/s0960-894x(00)00385-1. Bioorg Med Chem Lett. 2000. PMID: 10987423

9

Pharmacokinetics and pharmacodynamics of L-703,014, a potent fibrinogen receptor antagonist, after intravenous and oral administration in the dog.

Barrett JS, Gould RJ, Ellis JD, Holahan MM, Stranieri MT, Lynch JJ Jr, Hartman GD, Ihle N, Duggan M, Moreno OA, et al. Barrett JS, et al. Among authors: gould rj. Pharm Res. 1994 Mar;11(3):426-31. doi: 10.1023/a:1018973323039. Pharm Res. 1994. PMID: 8008711

10

Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217.

Cook JJ, Holahan MA, Lyle EA, Ramjit DR, Sitko GR, Stranieri MT, Stupienski RF 3rd, Wallace AA, Hand EL, Gehret JR, Kothstein T, Drag MD, McCormick GY, Perkins JJ, Ihle NC, Duggan ME, Hartman GD, Gould RJ, Lynch JJ Jr. Cook JJ, et al. Among authors: gould rj. J Pharmacol Exp Ther. 1996 Jul;278(1):62-73. J Pharmacol Exp Ther. 1996. PMID: 8764336

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

112 results

Search Page